Comparative Pharmacology
Head-to-head clinical analysis: HYDROCORTISONE SODIUM SUCCINATE versus KENALOG IN ORABASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCORTISONE SODIUM SUCCINATE versus KENALOG IN ORABASE.
HYDROCORTISONE SODIUM SUCCINATE vs KENALOG IN ORABASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone sodium succinate is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to produce anti-inflammatory, immunosuppressive, and anti-stress responses. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit fibroblast proliferation.
100–500 mg IV or IM every 2–6 hours, as needed; typical initial dose 100–250 mg IV bolus followed by 100–250 mg IV every 4–6 hours for acute conditions.
Apply a thin layer to the affected area 2-4 times daily, after meals and at bedtime. Do not rub in; allow to form a film.
None Documented
None Documented
1.5-2 hours (plasma terminal); biological half-life 8-12 hours (due to intracellular effects), requiring q6-8h dosing in adrenal insufficiency
Terminal half-life approximately 2-5 hours following mucosal application.
Renal (90-95% as metabolites, <5% unchanged); biliary/fecal <5%
Primarily hepatic metabolism; metabolites excreted renally (~75%) and in feces (~10%).
Category D/X
Category C
Corticosteroid
Corticosteroid